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Abstract and Keywords 
Background and objective: Residual neuromuscular block is an important postoperative 
complication due to the use of neuromuscular blocking drugs. The aim of this study was 
to access the incidence of residual neuromuscular block in a post-anaesthesia care unit. 
Methods: This observational prospective study was conducted in a post-anaesthesia care 
unit during a three-week period. Residual neuromuscular block was defined as train-of-
four ratio <0.9 and objectively quantified using acceleromyography in 202 eligible 
patients at recovery room admission. Patients with train-of-four ratio <0.9 were re-
assessed hourly. Demographic data, perioperative variables, lengths of stay in hospital 
and at recovery room, and critical respiratory events were recorded. Descriptive 
analyses of variables were used to summarize data. The Mann-Whiney U test, Chi-
square or Fisher’s exact test were used for comparisons. 
Results: Residual neuromuscular block incidence in the post-anaesthesia care unit was 
30.2%. Patients with residual neuromuscular block had a greater incidence of critical 
respiratory events (51% versus 16%, P<0.001) and greater incidence of each event 
considered independently: airway obstruction (5% versus 4%, P=0.029), mild-moderate 
hypoxemia (23% versus 2%, P<0.001), severe hypoxemia (7% versus 1%, P=0.033), 
respiratory failure (8% versus 1%, P=0.031), inability to breathe deeply (38% versus 
12%, P<0.001) and muscular weakness (16% versus 1%, P<0.001). Residual 
neuromuscular block was more common after high risk surgery (53% versus 33%, 
P=0.011) and was more often associated with post-operative hypoactive emergence as 
defined by the Richmond Agitation and Sedation Scale (21% versus 6%, P=0.001). 
Length of stay in the hospital and in recovery room was not significantly different 
between groups. 
Conclusions: This study suggests that residual neuromuscular block is common in the 
post-anaesthesia care unit. This condition was associated with critical respiratory events.  
 
Keywords: Neuromuscular blockade; postoperative complications; anaesthesia recovery 
period; recovery room.  
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Introduction 
When neuromuscular blocking drugs (NMBDs) are administered intraoperatively, 
residual neuromuscular block (RNMB) is often observed in the post-anaesthesia care 
unit (PACU).1-5 Studies have established an association between RNMB and increased 
postoperative morbidity and mortality, critical respiratory events, and longer PACU 
stays.6-8 
Train-of-four (TOF) nerve stimulation was introduced in the 1970s and is a commonly 
used method to access the status of neuromuscular block.9 It is difficult to exclude 
residual block using qualitative monitoring of TOF (tactile or visual), because of the 
subjectivity involved in these observations. Quantitative methods should be preferred 
and acceleromyography monitoring allows an accurate quantification of small degrees 
of residual block.10 The TOF ratio threshold that represents inadequate neuromuscular 
recovery, combined with signs and symptoms of muscle weakness, has changed over 
the decades. Initially, a TOF ratio >0.7 was considered to represent adequate 
neuromuscular recovery. However, current recommendations support a TOF ratio equal 
to or greater than 0.9 to ensure optimal patient safety.11,12 
Despite the use of short-acting NMBDs and pharmacological reversal of neuromuscular 
block, the incidence of RNMB on arrival to the PACU can be as high as 31%-64%.1-
5,11,12
 
An increase in the incidence of critical respiratory events (CRE) at the PACU even in 
the presence of small degrees of RNMB has been proved.7,13-16 Many factors related to 
patients, surgical procedure and anaesthetic management come into play. Patient risk 
factors include advanced age, male sex, chronic obstructive pulmonary disease, diabetes 
and obesity.14-16 Surgery-related variables include abdominal or orthopaedic surgery, 
emergency operation and long duration of surgery.14-16 Finally, the anaesthetic risk 
factors for CREs in the PACU include the use of general anaesthesia, opioids and 
NMBD.14,16 
Emergence is the transition from unconsciousness to full wakefulness, and ideally 
should be smooth and uneventful.17 Inadequate emergence is characterized by a 
disturbance of activity level in the immediate postoperative period. It can be classified 
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into two subtypes: emergence delirium, characterized by agitation, restlessness and 
hyperactivity; and hypoactive emergence, characterized by a delayed recovery after 
anaesthesia. Inadequate emergence after anaesthesia is a frequent complication. 
Preventable risk factors for emergence delirium are induction of anaesthesia with 
etomidate, premedication with benzodiazepines and higher postoperative pain scores.18 
Hypoactive emergence occurs less frequently than emergence delirium and is associated 
with a longer postoperative hospital stay.18 Thus, monitoring the sedation status in the 
PACU is important. The Richmond Agitation-Sedation Scale (RASS) has demonstrated 
excellent interrater reliability and criterion, construct, and face validity.19,20  
The primary aim of this investigation was to determine the incidence of RNMB in the 
PACU after general anaesthesia. The secondary aim was to examine the outcome 
related to critical respiratory events (CREs), PACU complications and the length of 
PACU and hospital stay. 
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Methods 
This study was approved by the Centro Hospitalar São João Ethics Committee, 
Alameda Hernâni Monteiro, 4200-319 Porto, Portugal (Chairperson Prof Filipe Nuno 
Alves Santos Almeida). Written informed consent was obtained from all participants. 
Hospital de São João, Porto, is a 1124-bed tertiary hospital in a major metropolitan area 
that serves 3,000,000 people. This prospective study was conducted in a 12-bed PACU 
between 8:00AM and 8:00PM, Monday through Friday, over a three-week period (from 
May 9th to May 27th, 2011). 
Inclusion criteria were the ability of patient to provide written informed consent, 
admission on spontaneous ventilation and intraoperative use of NMBDs. Exclusion 
criteria were patient refusal, incapacity of providing informed consent, a score of <25 in 
the mini-mental state examination (MMSE)21, age under 18 years, foreign nationality, 
known neuromuscular disease, urgent/emergent surgery and also cardiac surgery, 
neurosurgery or other procedures that required therapeutic hypothermia. 
Measurements 
The neuromuscular block was defined as TOF <0.9 and it was quantified at admission 
to the PACU using acceleromyography of the adductor pollicis muscle (TOF-Watch®). 
Two surface electrodes (Kendall ARBO Electrodes®) were attached to the cleansed 
skin over the ulnar nerve on the volar side of the wrist. The distal electrode was 
positioned where a proximal bending line crosses the radial side of the flexor carpi 
ulnaris muscle. The proximal electrode was placed 3 cm proximal of the distal 
electrode. The piezoelectric transducer was placed with its largest flat side against the 
volar aspect of the distal phalanx of the thumb. The stimulation current was set to 50 
mA. The resulting TOF ratios were obtained (4 pulses of 0.2 ms duration over 2 s at a 
frequency of 2 Hz). Three consecutive TOF measurements (separated by 15 s) were 
obtained, and the average of the 3 values was recorded. If a value differed from the 
others by more than 10%, an additional TOF measurement was obtained and the closest 
3 ratios were averaged. Neuromuscular block was re-assessed hourly while patients 
maintained TOF<0.9. The initial TOF ratios were measured before any therapeutic in 
the PACU.  
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A standardized data collection sheet was completed for each patient eligible for the 
study. The MMSE was preformed pre-operatively, when collecting the informed 
consent. The Revised Cardiac Risk Index (RCRI) was assessed.22 The patient 
demographic data recorded included age, gender, height, weight, American Society of 
Anesthesiologists physical status (ASA), pre-existing medical conditions, preoperative 
medications and an extensive check-list for cardiac risk. Intraoperative details included 
type of anaesthesia, type of surgical procedure, duration of anaesthesia, duration of 
surgery, intraoperative fluids (crystalloids, colloids or blood products), NMBD, time of 
last dose of relaxant and neuromuscular block reversers used. Patients’ tympanic 
temperature, blood pressure, cardiac frequency, peripheral oxygen saturation and mean 
TOF ratio were recorded on admission to the PACU. The length of PACU stay, the neck 
perimeter, and occurrence of CREs were also recorded. Each CRE was defined on the 
data collection sheet using the following criteria:7 
1. Upper airway obstruction requiring an intervention (jaw thrust, oral or nasal 
airway); 
2. Mild-moderate hypoxemia [oxygen saturations (SpO2) of 93%-90%]; 
3. Severe hypoxemia (SpO2 <90%); 
4. Signs of respiratory distress or impending ventilator failure (respiratory rate >20 
breaths per minute, accessory muscle use, tracheal tug); 
5. Inability to breathe deeply when requested; 
6. Symptoms of respiratory or upper airway muscle weakness (difficulty breathing, 
swallowing or speaking); 
7. Patient requiring reintubation in the PACU; 
8. Clinical evidence or suspicion of pulmonary aspiration after tracheal extubation 
(gastric contents observed in the oropharynx and hypoxemia). 
Inadequate emergence was classified in its different forms according to the Richmond 
Agitation-Sedation Scale (RASS) applied at discharge.19,20 Emergence delirium was 
defined as a RASS score ≥+1, and hypoactive emergence was defined as a RASS score 
≤−2.18 
PACU discharge times were recorded by PACU nurses not involved in this study. 
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Statistical analysis 
Descriptive analyses of variables were used to summarize data. 
Ordinal and continuous data found not to follow a normal distribution, based on the 
Kolmogorov–Smirnov test for normality of the underlying population, are presented as 
median and interquartile range. Normally distributed data is presented as mean and 
standard deviation (SD). 
An univariate analysis was performed to identify determinants for RNMB using the 
Mann-Whitney U test to compare continuous variables and Chi-square or Fisher’s exact 
test to compare proportions between two groups of subjects.  
Differences were considered statistically significant when P was <0.05. 
Data was analysed using SPSS software for Windows Version 19.0 (SPSS Inc., 
Chicago, IL, USA).  
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Results 
From the 357 patients consecutively admitted in the PACU during the study period, a 
total of 202 patients were studied. Seventeen patients were excluded: 7 patients were 
admitted in a surgical intensive care unit, 3 patients were incapable of providing 
informed consent or had a Mini Mental Status Examination <25, 3 patients were not 
submitted to surgery, 1 patient was submitted to neurosurgical surgery, 1 was less than 
18 years old, 1 did not speak Portuguese and 1 refused to participate. One hundred and 
thirty-seven patients did not meet the inclusion criteria. One patient was not assessed 
due to the impossibility to perform TOF measurements as planed (patient had plaster on 
both arms). 
In this study were included 79 (39%) male and 123 (61%) female patients. The median 
patient age was 54 years (41 – 66) and body mass index was 26 kg m-2 (23 – 30). Forty-
five patients (22%) were scored as ASA I, 132 (65%) as ASA II, 24 (12%) as ASA III 
and 1 (1%) as ASA IV. Seventy-nine patients (39%) underwent high risk surgery. Fifty-
three patients (26%) presented CRE: 40 (20%) were unable to breathe deeply when 
requested, 20 (10%) developed mild-moderate hypoxemia, 11 (5%) symptoms of 
respiratory or upper airway muscle weakness, 7 (4%) signs of respiratory distress, 5 
(3%) severe hypoxemia and 3 (2%) upper airway obstruction. (Table 1) 
On arrival in the PACU, 61 patients (30.2%) were found to have RNMB with a mean 
TOF ratio of 75% (62-84). (Tables 1 and 2) 
The incidence of CRE in the PACU was 26%. Patients with RNMB had a CRE 
incidence significantly high when compared to patients with adequate recovery of 
neuromuscular transmission [31 (51%) versus 22 (16%), P<0.001]. This also applies to 
each CRE independently: airway obstruction (5% versus 4%, P=0.029), mild-moderate 
hypoxemia (23% versus 2%, P<0.001), severe hypoxemia (7% versus 1%, P=0.033), 
respiratory failure (8% versus 1%, P=0.031), inability to breathe deeply (38% versus 
12%, P<0.001) and muscular weakness (16% versus 1%, P<0.001). (Table 3) 
Time from last dose of relaxant to arrival in PACU was shorter in patients with RNMB 
[63 min (47-105) versus 90 min (64-124), P=0.012]. Neostigmine had been 
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administered to 98% of patients with RNMB and to 81% of patients with TOF>0.9. 
(Table 2) 
RNMB was also significantly more common after high risk surgery, as defined by the 
Revised Cardiac Risk Index (53% versus 33%, P=0.011). Patients with TOF<0.90 were 
more often associated with post-operative hypoactive emergence as defined by the 
Richmond Agitation and Sedation Scale (21% versus 6%, P=0.001). (Table 2) 
Patients with and without RNMB did not differ in terms of age, gender, body mass 
index or ASA physical status. Length of hospital and PACU stays were also not 
different for patients with RNMB.  
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Discussion 
The main findings of this study were that residual neuromuscular block was very 
frequent in the post-anaesthesia care unit and that it had an incidence of 30.2%. In 
addition, RNMB was more common after high-risk surgery and was associated with a 
shorter time interval between last dose of NMBD and admission to the PACU. Residual 
block was also associated with a higher incidence of post-operative critical respiratory 
events and hypoactive emergence. 
Many European institutions have reported the practice of not administering reversal 
agents.1,2,23 In the hospital where this study took place, however, it is common practice 
to use reversal agents in all patients as standard of care. This may account for the 
clinically significant but relatively low RNMB incidence of 30.2% observed. Many 
factors contribute to RNMB, including demographic variables such as history of chronic 
obstructive lung disease, the type and duration of surgery, major abdominal and thoracic 
surgery, general anaesthesia (as opposed to regional anaesthesia) and anaesthesia 
involving pancuronium.13,14,24 These risk factors were controlled in the present study. 
(Table 2) 
The incidence of CRE in this study was 26%. The group with RNMB presented a higher 
incidence of CRE when compared with the group with adequate neuromuscular 
recovery. This can be explained by the many risk factors for CREs, as already stated. 
Interestingly, the percentage of patients to whom neostigmine was administered was 
higher in the RNMB group than in the group with adequate neuromuscular recovery. 
(Table 2) This is somewhat unexpected and an observer effect may have affected the 
decision-making process. Although most of the anaesthesiologists routinely 
administered a relaxant reversal, some might have used subjective criteria. In the latter 
situation, patients that received neostigmine were probably already at a higher risk of 
developing RNMB (due to a shorter time interval since the last dose of NMBD and the 
end of surgery, for example). On the other hand, patients with a longer time interval 
since the last dose of NMBD and the end of surgery may have not received neostigmine 
because RNMB was not likely. This might have led to the administration of relaxant 
reversal more frequently in patients that were bound to have RNMB anyway. 
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Two other associations were found. First, the patients that underwent high risk surgery 
presented a higher incidence of RNMB in the PACU. High risk surgery was defined 
according to the Revised Cardiac Risk Index (RCRI).22 The RCRI is a score defined to 
predict major cardiac events in non-cardiac surgery. It states six independent predictors 
and one of them is “high risk surgical procedure”, which includes intraperitoneal, 
intrathoracic and suprainguinal vascular surgery. 
Second, patients with RNMB were more hypoactive in the PACU. Hypoactive 
emergence was defined according to the RASS score (RASS ≤−2).18 Abdominal surgery 
is a stated risk factor associated with hypoactive delirium.25 In this way, abdominal 
surgery might be connected to the association found between high risk surgery and the 
incidence of RNMB and also the fact that patients with RNMB were more prone to the 
development of hypoactive delirium. 
Although a recent study has suggested that RNMB delayed recovery room discharge no 
difference was detected between the two groups in the present study.8 Hospital stays 
were also non-statistically different between groups. Duration of anaesthesia and 
duration of surgery were not associated with RNMB either. 
The results of this study must be considered within the context of its limitations. This 
was an observational prospective study. There was no intervention on anaesthetic 
practices before, during or after surgery and all treatments and therapeutics were of the 
responsibility of the colleague assigned to PACU duty that day. The data collection took 
place during a limited period of time, resulting in a reduced sample size. In addition, the 
sample of patients may not have been representative of all cases due to sampling bias. 
Notably neglected were patients under 18 years-old; foreign patients; patients submitted 
to ambulatory, emergent/urgent, cardiac and neurosurgery; patients admitted to the 
long-term PACU; and patients not operated in the Central Operating Room. One cannot 
exclude that other non-measured factors may have acted as confounders in this study. 
Finally, acceleromyography is a quantitative method but there are technical and 
operator-related issues that must be taken into account. Therefore, some interpersonal 
variability and random error cannot be excluded. To minimise this, TOF-measurement 
training took place prior to the data collection. It must also be recognized that even high 
stimulating currents such as the 50 mV used may not be supramaximal in some patients. 
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Nevertheless, this study has clinical implications. Departmental guidelines should 
encourage the use of quantitative neuromuscular transmission monitoring on all patients 
receiving NMBD. This evidence is not as obvious when reversal agents are used 
routinely.26 Special attention to these patients must be taken in the PACU setting, as 
they have a higher risk of postoperative complications, as shown. 
Intraoperative acceleromyographic monitoring was shown to reduce the risk of RNMB 
and CRE in the PACU.27 Future studies should confirm this suggestion and fundament 
new guidelines to reduce RNMB and its complications. 
In conclusion, the RNMB incidence in the PACU throughout this study was 30.2%. An 
association between RNMB and increased CRE incidence, high risk surgery and 
hypoactive emergence was also observed.  
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Tables 
Table 1 Characteristics of patients 
 (n = 202) 
Age (years) 54 (41-66) 
Sex (male/female) 79 (39) / 123 (61) 
BMI (kg m-2) 26 (23-30) 
ASA 
I/II 
III/IV/V 
 
117 (88) 
25 (12) 
RCRI 
High-risk type of surgery 
Ischemic heart disease 
History of congestive heart failure 
History of cerebrovascular disease 
Insulin therapy for diabetes 
Preoperative serum creatinine >2.0 mg dL-1 
 
79 (39) 
8 (4) 
9 (5) 
2 (1) 
17 (8) 
4 (4) 
RCRI 
RCRI ≤2 
RCRI >2 
 
195 (96) 
7 (4) 
COPD 9 (5) 
Hypertension 73 (36) 
Hyperlipidaemia 53 (26) 
Risk of surgery 
Minor 
Medium 
Major 
 
29 (14) 
156 (77) 
17 (8) 
Type of anaesthesia 
General anaesthesia 
Combined anaesthesia 
 
181 (90) 
21 (10) 
Intraoperative fluids 
Intravenous crystalloids (L) 
Intravenous colloids (L) 
Packed erythrocytes (Units) 
Fresh frozen plasma (Units) 
 
1.642 ± 1.218 
39.6 ± 160.6 
11.1 ± 62.6 
0 ± 0 
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Duration of surgery (min) 105 (70-162) 
Duration of anaesthesia (min) 140 (100-210) 
Temperature at PACU admission (ºC) 
<35ºC 
35.2 (34.8-35.6) 
80 (40) 
Length of PACU stay (min) 100 (73-140) 
Length of Hospital stay (days) 4 (2-7) 
At PACU admission 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (bpm) 
SpO2 (%) 
 
130 ± 25 
70 ± 14 
76 ± 17 
96 ± 4 
TOF mean 
TOF mean <90 
TOF mean <80 
TOF mean <70 
TOF mean <60 
90 ± 15 
30.2% 
18.3% 
12.4% 
7% 
Critical Respiratory Events  
Upper airway obstruction 
Mild-moderate hypoxia 
Severe hypoxia 
Respiratory distress 
Inability to breathe deepely 
Upper airway muscle weakness 
53 (26) 
3 (2) 
20 (10) 
5 (3) 
7 (4) 
40 (20) 
11 (5) 
Values are number (percentage), median (range) or mean ± SD. ASA, American Society of 
Anesthesiologists physical status; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
PACU, post-anaesthesia care unit; RCRI, revised cardiac risk index; SD, standard deviation; TOF, train-
of-four ratio.  
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Table 2 Characteristics of patients with (TOFm <90) and without (TOFm >90) 
neuromuscular residual block 
 
TOFm <90 
 (n = 61) 
TOFm >90 
(n = 141) P 
Age (years) 55 (41-68) 53 (41-65) 0.666 
Sex (male/female) 21(34) / 40(66) 58 (41) / 83 (59) 0.370 
BMI (kg m-2) 26 (24-31) 26 (23-30) 0.878 
ASA 
I/II 
III/IV/V 
 
53 (87) 
8 (13) 
 
124 (86) 
17 (12) 
0.834 
 
 
RCRI 
High-risk type of surgery 
Ischemic heart disease 
History of congestive heart failure 
History of cerebrovascular disease 
Insulin therapy for diabetes 
Preoperative serum creatinine >2.0mg dL-1 
 
32 (53) 
4 (7) 
2 (3) 
1 (2) 
5 (8) 
2 (3) 
 
47 (33) 
4 (3) 
7 (5) 
1 (1) 
12 (9) 
6 (4) 
 
0.011 
0.213 
0.594 
0.540 
0.941 
0.744 
RCRI 
RCRI ≤2 
RCRI >2 
 
59 (97) 
2 (3) 
 
136 (96) 
5 (2) 
0.924 
 
 
Duration of surgery (min) 105 (70-158) 100 (70-163) 0.646 
Duration of anaesthesia (min) 140 (100-210) 140 (98-210) 0.975 
Time (min) from last dose of NMBD to 
arrival in PACU 
63 (47-105) 90 (64-124) 0.012 
Patients given suxamethonium 13 (22) 17 (12) 0.059 
Patients given neostigmine 59 (98) 115 (81) 0.005 
Post-operative hypoactive (RASS≤2) 13 (21) 8 (6) 0.001 
Temperature at PACU admission (ºC) 
<35ºC 
35.2 (34.8-35.5) 
27 (44) 
35.2 (34.8-35.8) 
53 (38) 
0.463 
 
SpO2 at PACU admission (%) 97 (95-99) 96 (95-98) 0.148 
TOF mean (%) 75 (62-84) 97 (95-99) <0.001 
Length of PACU stay (min) 100 (74-136) 100 (73-140) 0.901 
Length of Hospital stay (days) 5 (2-7) 4 (2-7) 0.422 
Values are number (percentage), median (range) or mean ± SD. ASA, American Society of 
Anesthesiologists physical status; BMI, body mass index; NMBD, neuromuscular blocking drug; PACU, 
post-anaesthesia care unit; RASS, Richmond agitation-sedation scale; RCRI, revised cardiac risk index; 
SD, standard deviation; SpO2, oxygen saturation; TOFm, train-of-four ratio mean.  
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Table 3 Incidence of critical respiratory events in patients with (TOFm <90) and 
without (TOFm >90) neuromuscular residual block in the post-anaesthesia care 
unit 
 
TOFm <90 
(n = 61) 
TOFm >90 
(n = 141) P 
Critical Respiratory Events 31 (51) 22 (16) <0.001 
Upper airway obstruction 3 (5) 6 (4) 0.029 
Mild-moderate hypoxia 14 (23) 6 (4) <0.001 
Severe hypoxia 4 (7) 1 (1) 0.033 
Respiratory distress 5 (8) 2 (1) 0.031 
Inability to breathe deepely 23 (38) 17 (12) <0.001 
Upper airway muscle weakness 10 (16) 1 (1) <0.001 
Values are number (percentage) of patients. TOFm, train-of-four ratio mean. 
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